|
|
 |
|
|
|
 |
| Market Cap | 192.43M | EPS (ttm) | -0.00 |
| P/E | - | EPS this Y | 48.30% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 29.40% |
| P/S | 0.48 | EPS next 5Y | 25.00% |
| P/B | 1.94 | EPS Q/Q | 380.90% |
| Dividend | - | Sales Q/Q | 4.10% |
| Insider Own | 3.60% | Inst Own | 56.30% |
| Insider Trans | 0.00% | Inst Trans | -4.29% |
| Short Float | 0.41% | Earnings | Aug 09/a |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 912.26K | 52W Range | 1.18 - 3.39 |
|
|
|
|
| Hill International, Inc. provides project and construction management, and other consulting services primarily for buildings, transportation, environmental, energy, and industrial markets. The company offers program management, project management, construction management, project management oversight, troubled project turnaround, staff augmentation, project labor agreement consulting, commissioning, estimating and cost management, and labor compliance and facilities management services. It primarily serves the United States federal, state, and local governments; other national governments; and the private sector. The company operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Hill International, Inc. was founded in 1976 and is headquartered in Philadelphia, Pennsylvania. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| EVANS PAUL J. | Director | Nov 15 | Buy | 2.22 | 9,999 | 22,159 | 425,000 | Nov 16 05:46 PM | | EVANS PAUL J. | Director | Sep 28 | Buy | 2.04 | 10,725 | 21,858 | 415,001 | Sep 29 04:14 PM |
|
|
|
 |
| Market Cap | 968.43M | EPS (ttm) | -4.00 |
| P/E | - | EPS this Y | -13.60% |
| Forward P/E | - | EPS next Y | 5.10% |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 2.30 | EPS Q/Q | -19.50% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 0.90% | Inst Own | 88.90% |
| Insider Trans | 0.00% | Inst Trans | 0.16% |
| Short Float | 3.63% | Earnings | Aug 05/b |
| Analyst Recom | 1.50 | Target Price | 29.43 |
| Avg Volume | 1.33M | 52W Range | 4.95 - 25.21 |
|
|
|
|
| Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kelly Patrick F. | SVP, Chief Medical Officer | Apr 08 | Option Exercise | 5.05 | 15,000 | 75,750 | 104,884 | Apr 14 06:10 PM | | Kelly Patrick F. | SVP, Chief Medical Officer | Feb 23 | Sale | 9.78 | 5,245 | 51,283 | 64,884 | Feb 25 05:08 PM | | Lee Frank D. | President and CEO | Feb 23 | Sale | 9.78 | 17,981 | 175,809 | 79,769 | Feb 25 05:08 PM | | Potts Jeannette | See Remarks | Feb 23 | Sale | 9.78 | 4,672 | 45,680 | 22,358 | Feb 25 05:01 PM | | Shegog Todd | SVP, Chief Financial Officer | Feb 23 | Sale | 9.78 | 5,687 | 55,605 | 22,813 | Feb 25 05:04 PM |
|
|
|
 |
| Market Cap | 51.03M | EPS (ttm) | -2.08 |
| P/E | - | EPS this Y | 32.90% |
| Forward P/E | - | EPS next Y | 68.50% |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 0.86 | EPS Q/Q | 41.40% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 2.10% | Inst Own | 59.50% |
| Insider Trans | 4.55% | Inst Trans | -2.82% |
| Short Float | 0.88% | Earnings | Aug 05/b |
| Analyst Recom | 3.00 | Target Price | 1.20 |
| Avg Volume | 1.69M | 52W Range | 0.97 - 4.62 |
|
|
|
|
| IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Leonard Braden Michael | 10% Owner | Jun 16 | Buy | 1.11 | 83,199 | 92,243 | 3,017,774 | Jun 21 09:48 AM | | Leonard Braden Michael | 10% Owner | Jun 06 | Buy | 1.16 | 2,630 | 3,051 | 2,934,575 | Jun 07 04:12 PM | | Leonard Braden Michael | 10% Owner | Jun 03 | Buy | 1.14 | 30,800 | 34,976 | 2,931,945 | Jun 07 04:12 PM | | Leonard Braden Michael | 10% Owner | May 17 | Buy | 1.26 | 26,145 | 32,836 | 2,901,145 | May 18 11:00 AM | | Leonard Braden Michael | 10% Owner | May 16 | Buy | 1.17 | 15,000 | 17,577 | 2,875,000 | May 18 11:00 AM |
|
|
| |
 |
| Market Cap | 14.53B | EPS (ttm) | 1.76 |
| P/E | 76.37 | EPS this Y | 17.40% |
| Forward P/E | 61.83 | EPS next Y | 2422.20% |
| PEG | 13.54 | EPS past 5Y | 25.30% |
| P/S | 5.86 | EPS next 5Y | 5.64% |
| P/B | 2.44 | EPS Q/Q | -32.50% |
| Dividend | - | Sales Q/Q | -1.30% |
| Insider Own | 0.30% | Inst Own | 82.20% |
| Insider Trans | -17.82% | Inst Trans | 2.85% |
| Short Float | 4.91% | Earnings | Jul 28/a |
| Analyst Recom | 2.70 | Target Price | 120.57 |
| Avg Volume | 2.43M | 52W Range | 59.60 - 135.20 |
|
|
| Sep-08-22 | Upgrade |
Goldman |
Sell → Buy |
$60 → $172 |
|
|
|
|
| First Solar, Inc. provides photovoltaic (PV) solar energy solutions in the United State, Japan, France, Canada, India, Australia, and internationally. The company designs, manufactures, and sells cadmium telluride solar modules that converts sunlight into electricity. It serves developers and operators of systems, utilities, independent power producers, commercial and industrial companies, and other system owners. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gloeckler Markus | Chief Technology Officer | Aug 18 | Sale | 118.74 | 465 | 55,214 | 1,373 | Aug 19 04:03 PM | | Gloeckler Markus | Chief Technology Officer | Aug 17 | Option Exercise | 0.00 | 844 | 0 | 2,217 | Aug 19 04:03 PM | | Gloeckler Markus | Chief Technology Officer | Aug 17 | Sale | 115.14 | 478 | 55,037 | 1,373 | Aug 19 04:03 PM | | KENNEDY R CRAIG | Director | Aug 15 | Sale | 117.41 | 600 | 70,446 | 19,785 | Aug 17 04:27 PM | | ANTOUN GEORGES | Chief Commercial Officer | Aug 05 | Buy | 100.53 | 9,946 | 999,871 | 37,300 | Aug 05 06:04 PM |
|
|
|
 |
| Market Cap | 4.61B | EPS (ttm) | -5.00 |
| P/E | - | EPS this Y | -19.30% |
| Forward P/E | - | EPS next Y | 39.10% |
| PEG | - | EPS past 5Y | -14.20% |
| P/S | 19.63 | EPS next 5Y | 37.00% |
| P/B | 37.77 | EPS Q/Q | -12.60% |
| Dividend | - | Sales Q/Q | 50.40% |
| Insider Own | 1.90% | Inst Own | - |
| Insider Trans | -2.96% | Inst Trans | 2.59% |
| Short Float | 9.24% | Earnings | Aug 08/a |
| Analyst Recom | 1.90 | Target Price | 66.63 |
| Avg Volume | 3.25M | 52W Range | 21.65 - 73.02 |
|
|
|
|
| Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Farrow Jeffrey S | Chief Financial Officer | Sep 01 | Sale | 68.00 | 31,441 | 2,137,988 | 3,086 | Sep 06 07:00 PM | | Habibizad Nazila | See Remarks | Aug 18 | Sale | 67.19 | 4,678 | 314,315 | 8,918 | Aug 19 12:31 PM | | Svoronos Dawn | Director | Jun 21 | Sale | 27.24 | 1,908 | 51,983 | 5,376 | Jun 22 06:00 PM | | Pizzo Philip A. | Director | Jun 21 | Sale | 27.25 | 1,260 | 34,337 | 9,112 | Jun 22 06:00 PM | | Morrison Scott W | Director | Sep 09 | Sale | 30.21 | 4,800 | 145,003 | 3,037 | Sep 10 08:00 PM |
|
|
| |
 |
| Market Cap | 656.69M | EPS (ttm) | 1.28 |
| P/E | 17.83 | EPS this Y | 139.10% |
| Forward P/E | 22.46 | EPS next Y | 21.29% |
| PEG | 2.23 | EPS past 5Y | 46.70% |
| P/S | 3.82 | EPS next 5Y | 8.00% |
| P/B | 4.04 | EPS Q/Q | -59.10% |
| Dividend | - | Sales Q/Q | 3.10% |
| Insider Own | 2.80% | Inst Own | 95.40% |
| Insider Trans | -2.97% | Inst Trans | -4.42% |
| Short Float | 3.07% | Earnings | Aug 09/b |
| Analyst Recom | 2.00 | Target Price | 23.50 |
| Avg Volume | 356.47K | 52W Range | 11.89 - 29.42 |
|
|
|
|
| ChannelAdvisor Corporation, together with its subsidiaries, provides software-as-a-service (SaaS) solutions in the United States and internationally. The company's SaaS is a cloud platform that helps brands and retailers to improve their e-commerce operations, expand to new channels, and grow sales. Its suite of solutions includes various platform modules, including Marketplaces module that connects customers to third-party marketplaces, and allows brands and distributors to manage purchase orders, shipment notifications, stock quantities, and invoices for multiple retail dropship partners; Digital Marketing module that creates, manages, and evaluates advertising using a variety of ad formats across multiple channels; Shoppable Media module that allows brands to provide web visitors to purchase using dynamic links to in-stock retail product pages or carts, or with information on where products can be purchased from local retail stores; and Brand Analytics module, which helps brands for e-commerce channels with actionable insights into how products are performing across thousands of retailer websites and marketplaces. Its customers include online businesses of brands and retailers, as well as advertising agencies that use its solutions on behalf of their clients. The company was incorporated in 2001 and is headquartered in Morrisville, North Carolina. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Spitz David J | President and CEO | Aug 29 | Option Exercise | 8.64 | 31,250 | 270,000 | 419,734 | Aug 30 08:52 AM | | WINGO M SCOT | Director | Aug 22 | Sale | 15.35 | 3,250 | 49,888 | 28,001 | Aug 23 06:20 AM | | WINGO M SCOT | Director | Jul 20 | Sale | 14.91 | 3,250 | 48,458 | 31,251 | Jul 20 04:12 PM | | WINGO M SCOT | Director | Jun 21 | Sale | 14.48 | 3,250 | 47,060 | 34,501 | Jun 21 04:04 PM | | WINGO M SCOT | Director | May 13 | Sale | 12.88 | 15,000 | 193,200 | 37,751 | May 17 04:06 PM |
|
|
|
 |
| Market Cap | 3.69B | EPS (ttm) | -1.89 |
| P/E | - | EPS this Y | -123.80% |
| Forward P/E | - | EPS next Y | 59.10% |
| PEG | - | EPS past 5Y | -17.00% |
| P/S | 98.93 | EPS next 5Y | - |
| P/B | 15.51 | EPS Q/Q | 20.90% |
| Dividend | - | Sales Q/Q | 555.60% |
| Insider Own | 4.20% | Inst Own | 84.00% |
| Insider Trans | -6.74% | Inst Trans | 4.91% |
| Short Float | 11.10% | Earnings | Aug 09/a |
| Analyst Recom | 1.60 | Target Price | 52.00 |
| Avg Volume | 2.37M | 52W Range | 14.95 - 51.78 |
|
|
|
|
| ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| KANAYA SUSAN M | EVP, CFO and Sec. | Aug 16 | Option Exercise | 10.86 | 19,898 | 216,092 | 111,215 | Aug 18 04:48 PM | | KANAYA SUSAN M | EVP, CFO and Sec. | Aug 16 | Sale | 50.95 | 19,898 | 1,013,793 | 91,317 | Aug 18 04:48 PM | | KANAYA SUSAN M | EVP, CFO and Sec. | Aug 04 | Option Exercise | 6.50 | 46,298 | 300,805 | 137,615 | Aug 08 07:33 PM | | Schall Thomas J. | President and CEO | Aug 04 | Option Exercise | 14.28 | 130,000 | 1,856,400 | 2,523,352 | Aug 08 07:41 PM | | Tyree James L | Director | Aug 04 | Sale | 50.22 | 10,000 | 502,200 | 9,138 | Aug 08 07:27 PM |
|
|
| |
 |
| Market Cap | 2.83B | EPS (ttm) | 14.50 |
| P/E | 6.89 | EPS this Y | 19.70% |
| Forward P/E | 7.06 | EPS next Y | -14.13% |
| PEG | 0.69 | EPS past 5Y | 56.90% |
| P/S | 0.64 | EPS next 5Y | 10.00% |
| P/B | 0.99 | EPS Q/Q | -24.90% |
| Dividend | - | Sales Q/Q | 19.10% |
| Insider Own | 0.60% | Inst Own | - |
| Insider Trans | -22.57% | Inst Trans | -0.13% |
| Short Float | 12.41% | Earnings | Aug 05/b |
| Analyst Recom | 2.70 | Target Price | 98.50 |
| Avg Volume | 943.97K | 52W Range | 58.70 - 101.62 |
|
|
|
|
| Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services. It operates through two segments, Airline Operations and Dry Leasing. The company offers outsourced cargo and passenger aircraft operating solutions, including contractual service arrangements, such as the provision of aircraft; and value-added services, including crew, maintenance, and insurance to aircraft and other customers. It also provides cargo and passenger aircraft charter services to the U.S. Military Air Mobility Command, charter brokers, freight forwarders, direct shippers, airlines, manufacturers, sports teams and fans, and private charter customers; and cargo and passenger aircraft and engines dry leasing services. In addition, the company offers administrative and management support services, and flight simulator training services. It also serves express delivery providers, e-commerce retailers, and airlines. The company has operations in Africa, Asia, Australia, Europe, the Middle East, North America, and South America. Atlas Air Worldwide Holdings, Inc. was founded in 1992 and is headquartered in Purchase, New York. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| DIETRICH JOHN W | President & CEO | Aug 01 | Sale | 84.13 | 39,463 | 3,320,101 | 64,989 | Aug 03 05:41 PM | | Kokas Adam Richard | EVP, GC & Secty. | Mar 21 | Sale | 88.45 | 9,975 | 882,289 | 33,356 | Mar 23 07:38 AM | | Steen Michael | EVP & CMO | Jan 12 | Sale | 87.50 | 6,688 | 585,200 | 68,451 | Jan 13 05:01 PM | | Kokas Adam Richard | EVP, GC & Secty. | Jan 03 | Sale | 95.01 | 10,348 | 983,163 | 21,954 | Jan 04 05:20 PM | | Steen Michael | EVP & CMO | Dec 15 | Sale | 87.56 | 18,358 | 1,607,508 | 75,139 | Dec 16 05:59 PM |
|
|
|
 |
| Market Cap | 454.45M | EPS (ttm) | 0.39 |
| P/E | 25.81 | EPS this Y | 160.10% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 1.31 | EPS Q/Q | 301.60% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 0.39% | Inst Own | 96.70% |
| Insider Trans | 0.00% | Inst Trans | 1.63% |
| Short Float | 0.04% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 45.62K | 52W Range | 9.72 - 10.00 |
|
|
|
|
| H.I.G. Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida. |
|
|
 |
| Market Cap | 5.27B | EPS (ttm) | 0.53 |
| P/E | 12.48 | EPS this Y | 100.40% |
| Forward P/E | 3.10 | EPS next Y | -29.65% |
| PEG | - | EPS past 5Y | 15.00% |
| P/S | 0.51 | EPS next 5Y | -6.39% |
| P/B | 0.38 | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | 65.30% |
| Insider Own | 99.50% | Inst Own | 47.70% |
| Insider Trans | 0.00% | Inst Trans | 62.20% |
| Short Float | 5.01% | Earnings | - |
| Analyst Recom | 3.70 | Target Price | 4.35 |
| Avg Volume | 2.35M | 52W Range | 2.82 - 6.64 |
|
|
|
|
| YPF Sociedad Anonima, an energy company, engages in the oil and gas upstream and downstream activities in Argentina. The company's upstream operations include the exploration, development, and production of crude oil, natural gas, and NGLs. Its downstream operations include the refining, marketing, transportation, and distribution of oil, petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels, as well as in gas separation, natural gas distribution operations, and power generation. As of December 31, 2021, it had interests in 119 oil and gas fields; approximately 643 million barrels (mmbbl) of oil; and approximately 2,447 billion cubic feet (bcf) of gas. It also had a retail distribution network of 1,654 YPF-branded service stations; and 18 exploration permits. In addition, the company owns and operates three refineries with combined annual refining capacity of approximately 120 mmbbl; approximately 2,800 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; and crude oil tankage of approximately 7 mmbbl, as well as maintains terminal facilities at five Argentine ports. Further, it participates in 21 power generation plants with an aggregate installed capacity of 3,091 megawatts; offers diesel, fertilizers, lubricants, phytosanitary products, and ensiling bags; and supplies diesel, gasoline, fuel oil, coal, asphalts, paraffin, and sulfur, CO2, decanted oil, and aromatic extract. The company was founded in 1977 and is headquartered in Buenos Aires, Argentina. |
|
|
|
12next
|
|
|